ClinicalTrials.gov
skipnavHome|Search|Browse|Resources|Help|What's New|About

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

This study has been suspended.

Sponsored by: Memorial Sloan-Kettering Cancer Center
Information provided by: National Cancer Institute (NCI)

Purpose

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of 10-propargyl-10-deazaaminopterin in treating patients who have recurrent or refractory non-Hodgkin's lymphoma or Hodgkin's lymphoma.

Condition Treatment or Intervention Phase
adult Hodgkin's lymphoma
adult non-Hodgkin's lymphoma
 Drug: 10-propargyl-10-deazaaminopterin
 Procedure: chemotherapy
Phase II

MedlinePlus related topics:  Hodgkin's Disease;   Lymphoma

Study Type: Interventional
Study Design: Treatment

Official Title: Phase II Study of 10-Propargyl-10-Deazaaminopterin in Patients With Recurrent or Refractory Aggressive Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

Further Study Details: 

OBJECTIVES:

OUTLINE: This is an open-label study.

Patients receive 10-propargyl-10-deazaaminopterin IV over 1 hour on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) may receive 2 additional courses beyond the CR.

PROJECTED ACCRUAL: A total of 39-72 patients (12-35 for cohort 1 and 17-37 for cohort 2) will be accrued for this study within 10-36 months.

Eligibility

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

PATIENT CHARACTERISTICS: Age

Performance status

Life expectancy

Hematopoietic

Hepatic

Renal

Cardiovascular

Other

PRIOR CONCURRENT THERAPY: Biologic therapy

Chemotherapy

Endocrine therapy

Radiotherapy

Surgery

Other


Location Information


New York
      Memorial Sloan-Kettering Cancer Center, New York,  New York,  10021,  United States

Study chairs or principal investigators

Owen A. O'Connor, MD, PhD,  Study Chair,  Memorial Sloan-Kettering Cancer Center   

More Information

Study ID Numbers:  CDR0000258425; MSKCC-02078; NCI-H02-0100
Record last reviewed:  February 2004
Record first received:  January 24, 2003
ClinicalTrials.gov Identifier:  NCT00052442
Health Authority: Unspecified
ClinicalTrials.gov processed this record on 2004-10-29
line
U.S. National Library of Medicine, Contact NLM Customer Service
National Institutes of Health, Department of Health & Human Services
Copyright, Privacy, Accessibility, Freedom of Information Act